anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,152,972. Two-phase hair conditioning composition. SALES AFFILIATES Inc. 28 Feb., 1967 [27 May, 1966], No. 9583/67. Heading A5B. A two-phase hair conditioner comprises an aqueous phase containing a quaternary ammonium compound having at least 15 carbons and at least one saturated or unsaturated alkyl group containing at least 10 carbons, and a water imiscible liquid phase which is a non-solvent for the quaternary ammonium compound, has no water-solubilising groups and evaporates at room temperature at a rate similar to water. The quaternary ammonium compound may be oleyl dimethyl benzalkonium chloride, distearyl dimethyl ammonium chloride, or stearyl dimethyl benzyl ammonium chloride, and is suitably used in a quantity by weight of the water phase, of 0.03-1.0%. Suitable water imiscible liquids are hydrocarbons such as petroleum fractions distilling between 345 and 525F., for example deodorised kerosene and synthetic iso-paraffinic solvents such as Isopar, (registered Trade Mark) which is a mixture of 95% saturated branched chain isoparaffins with 5% naphthenic cycloparaffins. Other such liquids are halogenated hydrocarbons, such as chloroform, carbon tetrachloride, trichlorotrifluoroethane, and trichlorofluoromethane, or ketones, alcohols or ethers. Preferably a mixture of paraffins and halogenated hydrocarbons is used. The ratio of water phase to water-imiscible phase may be from 0.5 to 30:1, preferably 2 to 5:1, by volume. Other hair treatment agents may be incorporated into either phase depending upon their solubility in water or oil; for example the water phase can contain hair setting agents, e.g. mannitol or polyvinyl pyrrolidone and its vinyl acetate copolymer; water soluble sun-screening agents, e.g. 2-hydroxy-4-methoxybenzophenone-5-sulphonic acid; oxygen absorbing agents, e.g. monoethanolamine sulphite and optical brighteners e.g. pyrazoline sulphonic acid, or Tinopal, (Registered Trade Mark). The water-imiscible phase may contain oil soluble sun-screening agents, e.g. methylanthranilate or salicylate; oil soluble hair colourants, e.g. D and C Violet No. 2 and Red No. 17; lustre imparting substances, e.g. iso propyl myristate; nacreous agents, e.g. guanine crystals, and oil soluble optical brighteners. The invention includes a method of conditioning the hair by application of the composition.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including COXANTO, in pregnant women at about 30 weeks gestation and later. NSAIDs, including COXANTO, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age [see Use in Specific Populations (8.1)]. 

Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including COXANTO, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit COXANTO use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if COXANTO treatment extends beyond 48 hours. Discontinue COXANTO if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific Populations (8.1)].
Participants in this group will receive exercise counseling as per standard care for 10-weeks. This will include: (1) counseling on remaining active during chemotherapy; (2) handouts on the benefits of exercise during chemotherapy, exercise behavior change strategies, and how to exercise safely. Participants will be encouraged to remain as physical active as possible. As per American College of Sports Medicine 2019 guidelines, participants will be advised to take part in moderate intensity exercise for a total of 90 minutes per week.
Cannabis use stimulates calorie intake, but epidemiological studies show that people who regularly use it are leaner than those who don't. Two explanations have been proposed for this paradoxical finding. One posits that Δ9-tetrahydrocannabinol (THC) in cannabis desensitizes adipose CB1 cannabinoid receptors, stopping their stimulating effects on lipogenesis and adipogenesis. Another explanation is that THC exposure in adolescence, when habitual cannabis use typically starts, produces lasting changes in the developing adipose organ, which impacts adult systemic energy use. Here, we consider these possibilities in the light of a study which showed that daily THC administration in adolescent mice produces an adult metabolic phenotype characterized by reduced fat mass, partial resistance to obesity and dyslipidemia, and impaired thermogenesis and lipolysis. The phenotype, whose development requires activation of CB1 receptors in differentiated adipocytes, is associated with overexpression of myocyte proteins in the adipose organ with unchanged CB1 expression. We propose that adolescent exposure to THC causes lasting adipocyte dysfunction and the consequent emergence of a metabolic state that only superficially resembles healthy leanness. A corollary of this hypothesis, which should be addressed in future studies, is that CB1 receptors and their endocannabinoid ligands may contribute to the maintenance of adipocyte differentiation during adolescence.
The present invention relates to novel digestive system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "digestive system antigens", and the use of such digestive system antigens for detecting disorders of the digestive system, particularly the presence of cancer and cancer metastases. More specifically, isolated digestive system associated nucleic acid molecules are provided encoding novel digestive system associated polypeptides. Novel digestive system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human digestive system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the digestive system, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention . The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
BACKGROUND: Social environment may broadly impact multifaceted frailty; however, how environmental differences influence frailty in older adults with diabetes remains unclear. This study aimed to investigate regional differences in frailty in urban and rural areas among older adults with diabetes.
METHODS: This cross-sectional study was conducted as part of the frailty prevention program for older adults with diabetes study. Older adults aged 60-80 years who could independently perform basic activities of daily living (ADLs) were enrolled sequentially. Trained nurses obtained patient background, complications, body weight, body composition, blood tests, grip strength, frailty assessment, and self-care score results. Regional differences in frailty were evaluated using logistic and multiple linear regression analyses.
RESULTS: This study included 417 participants (269 urban and 148 rural). The prevalence of robustness was significantly lower in rural areas than in urban areas (29.7% vs. 43.9%, p = 0.018). Living in rural areas was associated with frailty (odds ratio [OR] 2.55, 95% confidence interval [CI] 1.38-4.71) and pre-frailty (OR 2.10, 95%CI 1.30-3.41). Lower instrumental ADL (B 0.28, standard error [SE] 0.073) and social ADL (B 0.265, SE 0.097) were characteristics of rural residents.
CONCLUSIONS: Regional differences in frailty were observed. Older adults with diabetes living in rural areas have a higher risk of frailty owing to a decline in instrumental and social ADLs. Social environment assessment and intervention programs that include communication strategies to enable care and social participation across environments are crucial to the effective and early prevention of frailty.
Methods of evaluating a compound for the ability to reduce a mental defect in a metazoan are provided, where the mental defect is caused by Fragile X syndrome, a tauopathy, Huntington's disease, neurofibromatosis 1, Parkinson's disease. The methods comprise determining whether the compound reduces a mental effect of the analogous disease in a Drosophila melanogaster. Also provided are methods of evaluating a compound for the ability to improve learning or memory in a mammal. The methods comprise determining whether the compound improves learning or memory in a Drosophila melanogaster that is deficient in a dFRMl. Additionally, methods of treatment of a mammal deficient in expression of an FMRl gene are provided. The methods comprise treating the mammal with a compound in a pharmaceutically acceptable excipient, where the compound inhibits expression or activity of a group II or group I  metabotropic glutamate receptor (mGluR), an inositol trisphosphate receptor (InsP3R), a glycogen synthase kinase-3ß (GSK-3ß), or a phosphodiesterase-4 (PDE-4) in the mammal.
Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
Chimeric antigen receptor (CAR) T-cell therapy leads to durable remissions in relapsed B-cell cancers, but treatment-associated immunocompromise leads to a substantial morbidity and mortality risk from atypical infection. Mucormycosis is an aggressive and invasive fungal infection with a mortality risk of 40-80% in patients with haematological malignancies. In this Grand Round, we report a case of mucormycosis in a 54-year-old patient undergoing CAR T-cell therapy who reached complete clinical control of Mucorales with combined aggressive surgical debridement, antifungal pharmacotherapy, and reversal of underlying risk factors, but with substantial morbidity from extensive oro-facial surgery affecting the patient's speech and swallowing. For broader context, we present our case alongside an US Food and Drugs Administration adverse events reporting database analysis and a review of the literature to fully evaluate the clinical burden of mucormycosis in patients treated with CAR T-cell therapy. We discuss epidemiology, clinical features, diagnostic tools, and current frameworks for treatment and prophylaxis. We did this analysis to promote increased vigilance for mucormycosis among physicians specialising in CAR T-cell therapy and microbiologists and to illustrate the importance of early initiation of therapy to effectively manage this condition. Mucormycosis prevention and early diagnosis, through targeted surveillance and mould prevention in patients at highest risk and Mucorales-specific screening assays, is likely to be key to improving outcomes in patients treated with CAR T-cell therapy.
This is an open-label, randomized, two-way, cross-over study to compare the glucose control between closed-loop strategy with and without a learning module. Children and adolescent type 1 diabetes patients at Camp Carowanis will be enrolled in the study, where they will undergo two randomly ordered interventions:

1. Closed-loop therapy: participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians on day 1 of camp. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. Camp physicians will review participants' sensor and insulin data daily, and if necessary, adjust participant basal rates and ICRs. The research staff members will likewise adjust the pump's basal rates and ICR settings as per physician's recommendations. The closed-loop therapy will last 2 days (48 hours).
2. Closed-loop therapy with learning module: participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each morning, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. Camp physicians will be to review the algorithm's recommendations before they are entered into the patient's pump. The closed-loop therapy with the learning module will last 8 days (192 hours).
The invention discloses an environment-friendly and light cured nail enamel with high dispersibility and a preparation method thereof. The nail enamel is prepared from the following raw materials in parts by weight: 55 to 65 parts of polyurethane acrylate, 18 to 22 parts of epoxy acrylate, 6 to 8 parts of 1,6-hexanediol diacrylate, 14 to 18 parts of light cured color paste, 3 to 5 parts of 2-methyl-1-(4-methylmercaptophenyl)-2-morpholine-1-actone, 3 to 5 parts of photo-initiator, and 2 to 4 parts of leveling agent. The prepared light cured color paste is in a liquid state, contains graphene, can be conveniently mixed with light sensitive resin, and barely affects the light curing speed. A black nail enamel is obtained. The color paste can be well dispersed in the nail enamel and has a certain modifying effect on resin. The obtained nail enamel has a proper adhesion force, can be well adhered on nails, and can also be easily peeled off from nails. People can remove the nail enamel without using an organic solvent, the harm to the nails is avoided, and the nail enamel is environment-friendly. The coating of the nail enamel is flexible.
An encapsulated product is provided containing a substance such as essential oil used in flavors and fragrances encapsulated in dyed cell wall-derived material such as from a fungus. The encapsulated product can be produced by contacting a microbial cell having an intact cell wall and which is preferably alive with the substance to be encapsulated, allowing the substance to diffuse through the cell wall into the microbial cell to encapsulate the substance and contacting the microbial cell with a dye to adsorb the dye to the surface of the cell wall to give a visible color to the cell wall. Alternatively, the microbial cell wall can be dyed before the microbial cell is contacted with the substance to be encapsulated. The cell wall can be dyed with a color associated with a naturally occurring source from which the substance encapsulated is obtained. For example, when the substance is lemon oil, the cell wall is dyed yellow. The encapsulated substance may be released from the microbial cell by chemical biodegradation or mechanical rupture of the cell wall. The encapsulated product can be used in foodstuffs to provide color and flavor, or for other uses where microcapsules are conventionally used.
Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
Psoriasis is a devastating autoimmune illness resulting from excessive keratinocyte growth and leukocyte infiltration into the dermis/epidermis. In the pathogenesis of psoriasis, different immune cells such as myeloid cells and CD4 + T cells play a key role. Th17/Th1 immune responses and oxidant-antioxidant responses are critical in regulation of psoriatic inflammation. Di-2-ethylhexyl phthalate (DEHP) is one of the well-known plasticizers and has widespread use worldwide. DEHP exposure through ingestion may produce harmful effects on the skin through systemic inflammation and oxidative stress, which may modify psoriatic inflammation. However, the effect of oral DEHP exposure on inflammatory cytokines and Nrf2/iNOS signaling in myeloid cells and CD4 + T cells in the context of psoriatic inflammation has not been investigated earlier. Therefore, this study explored the effect of DEHP on systemic inflammation in myeloid cells (IL-6, IL-17A, IL-23), Th17 (p-STAT3, IL-17A, IL-23R, TNF-α), Th1 (IFN-γ), Treg (Foxp3, IL-10), and Nrf2/iNOS signaling in imiquimod (IMQ)-induced mouse model of psoriasis-like inflammation. Our study showed increased Th17 signaling in imiquimod model which was further aggravated by DEHP exposure. Further, Nrf2 and iNOS signaling were also elevated in IMQ model where DEHP exposure further increased iNOS expression but did not modify the Nrf2 expression. Most importantly, IL-17A levels were also elevated in myeloid cells along with IL-6 which were further elevated by DEHP exposure. Overall, this study shows that IL-17A signaling is upregulated, whereas there is deficiency of Nrf2/HO-1 signaling by DEHP exposure in mice with psoriasiform inflammation. These observations suggest that DEHP aggravates IL-17A-mediated signaling both in CD4 + T cells as well as myeloid cells which is linked to exacerbation of IMQ-induced psoriatic inflammation in mice. Strategies that counteract the effect of DEHP exposure in the context of psoriatic inflammation through downregulation of IL-17A may be fruitful.
BACKGROUND: Data on population-based self-reported dual vision and hearing impairment are sparse in Europe. We aimed to investigate self-reported dual sensory impairment (DSI) in European population.
METHODS: A standardised questionnaire was used to collect medical and socio-economic data among individuals aged 15 years or more in 29 European countries. Individuals living in collective households or in institutions were excluded from the survey.
RESULTS: Among 296 677 individuals, the survey included 153 866 respondents aged 50 years old or more. The crude prevalence of DSI was of 7.54% (7.36-7.72). Among individuals aged 60 or more, 9.23% of men and 10.94% of women had DSI. Eastern and southern countries had a higher prevalence of DSI. Multivariable analyses showed that social isolation and poor self-rated health status were associated with DSI with ORs of 2.01 (1.77-2.29) and 2.33 (2.15-2.52), while higher income was associated with lower risk of DSI (OR of 0.83 (0.78-0.89). Considering country-level socioeconomic factors, Human Development Index explained almost 38% of the variance of age-adjusted prevalence of DSI.
CONCLUSION: There are important differences in terms of prevalence of DSI in Europe, depending on socioeconomic and medical factors. Prevention of DSI does represent an important challenge for maintaining quality of life in elderly population.
A 13.3% solution of sterile, pyrogen-free \[U-13C\]glucose in sterile water will be infused intravenously rapidly over 10 minutes to a total dose of 8 grams (bolus dose). Then the infusion will change to a rate of 4 grams/ hour. The infusion will continue until the time of tumour excision or biopsy, planned 2-3 hours.
In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Inactive marijuana (0% THC) served as a placebo comparator. Participants received an inactive marijuana cigarette (0% THC; provided by NIDA) in 1 of the 3 outpatient sessions in randomized order.
INTRODUCTION: Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid-sparing drug in patients with CEP.
MATERIALS AND METHODS: The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated.
RESULT: In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed.
CONCLUSIONS: Omalizumab can be an effective treatment for CEP and can be used as a steroid-sparing agent.